Product logins

Find logins to all Clarivate products below.


How Receptive Are Ophthalmologists and U.S. Payers to Emerging Therapies in This Underserved Market?

Affecting more than 40 million people in its severe form, dry eye disease represents a large, commercially attractive market that is currently underserved across the major markets in our study, of which only Japan can claim more than one approved prescription drug for the disease. Since the FDA approval of the immunosuppressant cyclosporine ophthalmic emulsion 0.05% (Actavis’s [formerly Allergan’s] Restasis) over a decade ago, no other prescription medicine has been specifically approved for dry eye in the United States, and one prescription drug has been recently approved for dry eye in Europe. Significant opportunity exists for additional therapies that target inflammation as well as other disease pathways characteristic of dry eye.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…